assoc. prof. perl | phase iii study of gilteritinib vs salvage ctx in r/r flt3 mutation aml
Published 7 years ago • 189 plays • Length 3:01Download video MP4
Download video MP3
Similar videos
-
4:35
admiral trial results: gilteritinib versus salvage chemotherapy in patients with flt3-mutated re...
-
9:39
alexander perl, md: the new flt3 inhibitor gilteritinib is “well-tolerated” in aml
-
7:36
alexander perl, eha 2019 – the phase iii admiral trial
-
1:10
assoc. prof. altman | molecular response to gilteritinib, a flt3i, in r/r aml, flt3
-
1:33
what effect does gilteritinib have on flt3 mutated relapsed/refractory aml?
-
6:38
gilteritinib plus venetoclax for r/r flt3-mutated aml
-
1:43
survival improves with gilteritinib in flt3 aml
-
3:17
prof. neil shah | ash 2017 | gilteritinib resistance in r/r flt3-mutated aml
-
2:12
gilteritinib prolongs os in flt3 r/r aml: phase 3 admiral results
-
20:58
new findings and improved outcomes in the treatment of aml
-
1:35
flt3 inhibitor maintenance after allo-sct for aml
-
1:29
flt3 mutations in aml
-
4:14
what are the future prospects for flt3 mutated aml?
-
4:03
a phase i/ii study evaluating quizartinib plus decitabine and venetoclax in flt3-mutated aml
-
2:44
phase i/ii study of novel flt3 inhibitor hm43239 in r/r aml
-
1:30
moving to the frontline: gilteritinib plus chemo for newly diagnosed aml
-
1:23
the promise of combining venetoclax with gilteritinib for the treatment of flt3-mutated aml
-
58:13
optimising transplant outcome in adults allografted for aml
-
2:26
improving outcomes for flt3-mutated r/r aml